Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,242JPY
6:00am GMT
Change (% chg)

¥-14 (-0.62%)
Prev Close
¥2,256
Open
¥2,234
Day's High
¥2,249
Day's Low
¥2,212
Volume
2,017,300
Avg. Vol
1,203,487
52-wk High
¥2,748
52-wk Low
¥2,197

Latest Key Developments (Source: Significant Developments)

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Mitsubishi Tanabe Pharma completes purchase of NeuroDerm
Wednesday, 18 Oct 2017 

Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<>>.Purchase plan was announced on July 24.  Full Article

FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS
Tuesday, 30 Aug 2016 

Mitsubishi Tanabe Pharma <4508.T> : FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS . FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS .Says if approved, medicine will be commercialized, under brand name Radicava, through newly formed Mt Pharma America, Inc.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook
Monday, 14 Mar 2016 

Mitsubishi Tanabe Pharma Corp:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

Mitsubishi Tanabe Pharma announces result of early-retirement program
Wednesday, 3 Feb 2016 

Mitsubishi Tanabe Pharma Corp:Says 634 employees took up the offer of the early-retirement program announced on Oct. 30, 2015.Effective date of retirement is March 31.  Full Article

Mobileye deal boosts Israeli high-tech exits to $23 bln in 2017

TEL AVIV, Jan 3 Israeli high-tech acquisitions and initial public offering activity soared to $23 billion in 2017 from $10 billion in 2016 due to the $15.3 billion purchase of Mobileye by Intel Corp, data published on Wednesday showed.